| Symbol | AQST |
|---|---|
| Name | AQUESTIVE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 30 TECHNOLOGY DRIVE, WARREN, New Jersey, 07059, United States |
| Telephone | +1 908 941-1900 |
| Fax | — |
| — | |
| Website | https://www.aquestive.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Additional info from NASDAQ: |
New Form ARS - Aquestive Therapeutics, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016766 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Aquestive Therapeutics, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016763 <b>Size:</b> 3 MB
Read moreNew Form DEF 14A - Aquestive Therapeutics, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016757 <b>Size:</b> 6 MB
Read moreRobbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
Read moreINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
Read moreAQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
Read moreBarber Daniel 🟢 acquired 293.1K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) Transaction Date: Mar 07, 2025 | Filing ID: 004597
Read moreBoyd Peter E. 🟢 acquired 60.0K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) Transaction Date: Mar 07, 2025 | Filing ID: 004596
Read moreJung Cassie 🟢 acquired 60.0K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) Transaction Date: Mar 07, 2025 | Filing ID: 004595
Read moreBRAENDER LORI J 🟢 acquired 82.5K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) Transaction Date: Mar 07, 2025 | Filing ID: 004592
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06527937 | Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome | Phase2 | Allergic Reaction | Completed | 2024-07-17 | 2024-10-13 | ClinicalTrials.gov |
| NCT03679975 | Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Scle… | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2018-04-04 | 2018-12-21 | ClinicalTrials.gov |
| NCT03428360 | Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Ep… | Phase3 | Epilepsy | Completed | 2018-01-23 | 2020-06-25 | ClinicalTrials.gov |
| NCT01220167 | Three-way Crossover Study Comparing Ondansetron ODFS Administered With and With… | Phase1 | Healthy Participants | Completed | 2008-08-01 | 2008-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Epinephrine Injection | DRUG | Phase PHASE2 | Allergic Reaction | COMPLETED | NCT06527937 |
| DESF | DRUG | Phase PHASE2 | Allergic Reaction | COMPLETED | NCT06527937 |
| Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT03953820 |
| Riluzole Oral Soluble film (ROSF) 50 mg | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT03679975 |
| Riluzole Oral Soluble Film | DRUG | Phase PHASE2 | ALS | WITHDRAWN | NCT03457753 |
| Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | DRUG | Phase PHASE3 | Epilepsy | COMPLETED | NCT03428360 |
| Diazepam Buccal Film | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT03953820 |
| Diazepam Buccal Film 12.5 mg | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT03179891 |
| Zofran ODT (ondansetron 8 mg) without water | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Ondansetron 8 mg ODFS with water | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Ondansetron 8 mg ODFS without water | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |